Data / Drug companies / Allergan, Inc.
Allergan, Inc.: 70 products in the FDA NDC directory, labeler code 0023
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Allergan, Inc. (labeler code 0023) lists 70 products in the FDA National Drug Code Directory, covering 28 finished drugs by generic name. By type: 36 over the counter drugs, 26 prescription drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on July 9, 2026.
The request: Watch Allergan, Inc. (FDA labeler code 0023): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0023
- Products in commercial distribution
- 70
- Packages
- 145
- Finished drugs by generic name
- 28
- Prescription products
- 26
- Over the counter products
- 36
- Flagged as original packager
- 53 of 53 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- April 29, 1974
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 33 | 47.1% |
| New drug applications (NDA) | 24 | 34.3% |
| Drugs for further processing | 6 | 8.6% |
| Biologics (BLA) | 4 | 5.7% |
| Bulk ingredients | 2 | 2.9% |
| Unapproved homeopathic products | 1 | 1.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 36 | 51.4% |
| Prescription drugs | 26 | 37.1% |
| Drugs for further processing | 6 | 8.6% |
| Bulk ingredients | 2 | 2.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Carboxymethylcellulose sodium and glycerin | 6 | 1 |
| Carboxymethylcellulose sodium | 5 | 30 |
| Carboxymethylcellulose sodium, glycerin and polysorbate 80 | 4 | 1 |
| Onabotulinumtoxina | 4 | 2 |
| Carboxymethylcellulose sodium, glycerin | 3 | 6 |
| Bimatoprost | 3 | 15 |
| Mineral oil, petrolatum | 3 | 1 |
| Ketorolac tromethamine | 3 | 69 |
| Carboxymethylcellulose sodium, glycerin, polysorbate 80 | 3 | 1 |
| Cyclosporine | 2 | 24 |
| Progesterone | 2 | 39 |
| Ubrogepant | 2 | 2 |
| Oxybutynin | 2 | 6 |
| Salicylic acid | 2 | 330 |
| Brimonidine tartrate | 2 | 15 |
| Alcaftadine | 2 | 4 |
| Titanium dioxide and zinc oxide | 2 | 46 |
| Levonorgestrel | 1 | 31 |
| Octinoxate, octisalate, titanium dioxide and zinc oxide | 1 | 1 |
| Zinc oxide and octinoxate | 1 | 2 |
| Iron dextran | 1 | 3 |
| Arnica montana and ledum palustre twig | 1 | 1 |
| Brimonidine tartrate, timolol maleate | 1 | 1 |
| Carboxymethylcellulose sodium, glycerin, and polysorbate 80 | 1 | 1 |
| Gatifloxacin | 1 | 3 |
| Polyvinyl alcohol, povidone | 1 | 18 |
| Dexamethasone | 1 | 45 |
| Octinoxate, octisalate and zinc oxide | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution/ drops | 31 | 44.3% |
| Lotion | 6 | 8.6% |
| Liquid | 5 | 7.1% |
| Tablet | 4 | 5.7% |
| Gel | 4 | 5.7% |
| Injection, powder, lyophilized, for solution | 4 | 5.7% |
| Ointment | 3 | 4.3% |
| Patch | 3 | 4.3% |
| Emulsion | 2 | 2.9% |
| Kit | 2 | 2.9% |
| Powder | 2 | 2.9% |
| Implant | 2 | 2.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Carboxymethylcellulose sodium | 0023-8027 | Liquid | Drugs for further processing | July 9, 2026 |
| Carboxymethylcellulose sodium | 0023-8026 | Liquid | Drugs for further processing | July 2, 2026 |
| Refresh Optive Mega-3 PF | 0023-3988 | Solution/ drops | Over the counter monograph drugs | March 1, 2026 |
| Botulinum toxin type a | 0023-5028 | Powder | Drugs for further processing | November 4, 2024 |
| Botulinum toxin type a | 0023-5027 | Powder | Drugs for further processing | October 15, 2024 |
| REFRESH Optive Mega-3 | 0023-4230 | Solution/ drops | Over the counter monograph drugs | July 1, 2024 |
| SkinMedica Acne Clarifying Treatment | 0023-1230 | Lotion | Over the counter monograph drugs | April 9, 2024 |
| Refresh Relieva PF Xtra | 0023-3782 | Solution/ drops | Over the counter monograph drugs | March 1, 2024 |
| Refresh tears pf | 0023-3110 | Solution/ drops | Over the counter monograph drugs | March 1, 2024 |
| Botulinum toxin type a | 0023-1111 | Liquid | Bulk ingredients | February 29, 2024 |
| Lastacaft | 0023-4291 | Solution/ drops | New drug applications (NDA) | December 1, 2021 |
| REFRESH Optive Mega-3 | 0023-7151 | Solution/ drops | Over the counter monograph drugs | June 15, 2021 |
| Refresh RELIEVA PF | 0023-9537 | Solution/ drops | Over the counter monograph drugs | September 25, 2020 |
| Refresh RELIEVA PF | 0023-4515 | Solution/ drops | Over the counter monograph drugs | September 25, 2020 |
| OcuMend Healing Gels | 0023-6934 | Patch | Unapproved homeopathic products | September 1, 2020 |
| Refresh Digital PF | 0023-6954 | Solution/ drops | Over the counter monograph drugs | August 1, 2020 |
| Refresh Digital | 0023-6952 | Solution/ drops | Over the counter monograph drugs | August 1, 2020 |
| Durysta | 0023-9652 | Implant | New drug applications (NDA) | March 4, 2020 |
| Ubrogepant | 0023-6502 | Tablet | Drugs for further processing | December 23, 2019 |
| Ubrelvy | 0023-6501 | Tablet | New drug applications (NDA) | December 23, 2019 |
| Ubrogepant | 0023-6499 | Tablet | Drugs for further processing | December 23, 2019 |
| Ubrelvy | 0023-6498 | Tablet | New drug applications (NDA) | December 23, 2019 |
| Refresh Relieva Preservative Free | 0023-6634 | Solution/ drops | Over the counter monograph drugs | July 26, 2019 |
| Refresh Relieva | 0023-6630 | Solution/ drops | Over the counter monograph drugs | July 22, 2019 |
| REFRESH Optive Mega-3 | 0023-5773 | Solution/ drops | Over the counter monograph drugs | May 30, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.